BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31599373)

  • 1. Novel functional proteins coded by the human genome discovered in metastases of melanoma patients.
    Sanchez A; Kuras M; Murillo JR; Pla I; Pawlowski K; Szasz AM; Gil J; Nogueira FCS; Perez-Riverol Y; Eriksson J; Appelqvist R; Miliotis T; Kim Y; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Ekedahl H; Horvatovich P; Sugihara Y; Welinder C; Wieslander E; Kwon HJ; Domont GB; Malm J; Rezeli M; Betancourt LH; Marko-Varga G
    Cell Biol Toxicol; 2020 Jun; 36(3):261-272. PubMed ID: 31599373
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The human melanoma proteome atlas-Defining the molecular pathology.
    Betancourt LH; Gil J; Kim Y; Doma V; Çakır U; Sanchez A; Murillo JR; Kuras M; Parada IP; Sugihara Y; Appelqvist R; Wieslander E; Welinder C; Velasquez E; de Almeida NP; Woldmar N; Marko-Varga M; Pawłowski K; Eriksson J; Szeitz B; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Lindberg H; Oskolas H; Lee B; Berge E; Sjögren M; Eriksson C; Kim D; Kwon HJ; Knudsen B; Rezeli M; Hong R; Horvatovich P; Miliotis T; Nishimura T; Kato H; Steinfelder E; Oppermann M; Miller K; Florindi F; Zhou Q; Domont GB; Pizzatti L; Nogueira FCS; Horvath P; Szadai L; Tímár J; Kárpáti S; Szász AM; Malm J; Fenyö D; Ekedahl H; Németh IB; Marko-Varga G
    Clin Transl Med; 2021 Jul; 11(7):e473. PubMed ID: 34323403
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlation of histopathologic characteristics to protein expression and function in malignant melanoma.
    Welinder C; Pawłowski K; Szasz AM; Yakovleva M; Sugihara Y; Malm J; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Laurell T; Wieslander E; Marko-Varga G
    PLoS One; 2017; 12(4):e0176167. PubMed ID: 28445515
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical protein science in translational medicine targeting malignant melanoma.
    Gil J; Betancourt LH; Pla I; Sanchez A; Appelqvist R; Miliotis T; Kuras M; Oskolas H; Kim Y; Horvath Z; Eriksson J; Berge E; Burestedt E; Jönsson G; Baldetorp B; Ingvar C; Olsson H; Lundgren L; Horvatovich P; Murillo JR; Sugihara Y; Welinder C; Wieslander E; Lee B; Lindberg H; Pawłowski K; Kwon HJ; Doma V; Timar J; Karpati S; Szasz AM; Németh IB; Nishimura T; Corthals G; Rezeli M; Knudsen B; Malm J; Marko-Varga G
    Cell Biol Toxicol; 2019 Aug; 35(4):293-332. PubMed ID: 30900145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep-proteome mapping of WM-266-4 human metastatic melanoma cells: From oncogenic addiction to druggable targets.
    Konstantakou EG; Velentzas AD; Anagnostopoulos AK; Litou ZI; Konstandi OA; Giannopoulou AF; Anastasiadou E; Voutsinas GE; Tsangaris GT; Stravopodis DJ
    PLoS One; 2017; 12(2):e0171512. PubMed ID: 28158294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Plasma proteome alterations by MAPK inhibitors in BRAF
    Babačić H; Eriksson H; Pernemalm M
    Neoplasia; 2021 Aug; 23(8):783-791. PubMed ID: 34246984
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Challenging the heterogeneity of disease presentation in malignant melanoma-impact on patient treatment.
    Marcell Szasz A; Malm J; Rezeli M; Sugihara Y; Betancourt LH; Rivas D; Gyorffy B; Marko-Varga G
    Cell Biol Toxicol; 2019 Feb; 35(1):1-14. PubMed ID: 30357519
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Allele frequencies of BRAFV600 mutations in primary melanomas and matched metastases and their relevance for BRAF inhibitor therapy in metastatic melanoma.
    Satzger I; Marks L; Kerick M; Klages S; Berking C; Herbst R; Völker B; Schacht V; Timmermann B; Gutzmer R
    Oncotarget; 2015 Nov; 6(35):37895-905. PubMed ID: 26498143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Discovery of TBC1D7 as a Potential Driver for Melanoma Cell Invasion.
    Qi TF; Guo L; Huang M; Li L; Miao W; Wang Y
    Proteomics; 2020 Jul; 20(14):e1900347. PubMed ID: 32510182
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proteomic profiling of human melanoma metastatic cell line secretomes.
    Rocco M; Malorni L; Cozzolino R; Palmieri G; Rozzo C; Manca A; Parente A; Chambery A
    J Proteome Res; 2011 Oct; 10(10):4703-14. PubMed ID: 21815687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comprehensive DNA methylation study identifies novel progression-related and prognostic markers for cutaneous melanoma.
    Wouters J; Vizoso M; Martinez-Cardus A; Carmona FJ; Govaere O; Laguna T; Joseph J; Dynoodt P; Aura C; Foth M; Cloots R; van den Hurk K; Balint B; Murphy IG; McDermott EW; Sheahan K; Jirström K; Nodin B; Mallya-Udupi G; van den Oord JJ; Gallagher WM; Esteller M
    BMC Med; 2017 Jun; 15(1):101. PubMed ID: 28578692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protein deep sequencing evaluation of metastatic melanoma tissues.
    Welinder C; Pawłowski K; Sugihara Y; Yakovleva M; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Rezeli M; Jansson B; Laurell T; Fehniger T; Döme B; Malm J; Wieslander E; Nishimura T; Marko-Varga G
    PLoS One; 2015; 10(4):e0123661. PubMed ID: 25874936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transcriptomic Analysis Reveals Prognostic Molecular Signatures of Stage I Melanoma.
    Thakur R; Laye JP; Lauss M; Diaz JMS; O'Shea SJ; Poźniak J; Filia A; Harland M; Gascoyne J; Randerson-Moor JA; Chan M; Mell T; Jönsson G; Bishop DT; Newton-Bishop J; Barrett JH; Nsengimana J
    Clin Cancer Res; 2019 Dec; 25(24):7424-7435. PubMed ID: 31515461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gene signature of the metastatic potential of cutaneous melanoma: too much for too little?
    Tímár J; Gyorffy B; Rásó E
    Clin Exp Metastasis; 2010 Aug; 27(6):371-87. PubMed ID: 20177751
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feasibility study on measuring selected proteins in malignant melanoma tissue by SRM quantification.
    Welinder C; Jönsson G; Ingvar C; Lundgren L; Baldetorp B; Olsson H; Breslin T; Rezeli M; Jansson B; Laurell T; Fehniger TE; Wieslander E; Pawlowski K; Marko-Varga G
    J Proteome Res; 2014 Mar; 13(3):1315-26. PubMed ID: 24490776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study.
    Alonso SR; Ortiz P; Pollán M; Pérez-Gómez B; Sánchez L; Acuña MJ; Pajares R; Martínez-Tello FJ; Hortelano CM; Piris MA; Rodríguez-Peralto JL
    Am J Pathol; 2004 Jan; 164(1):193-203. PubMed ID: 14695333
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma.
    Solassol J; Du-Thanh A; Maudelonde T; Guillot B
    Int J Biol Markers; 2011; 26(2):82-7. PubMed ID: 21607923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Concordance in BRAF V600E status over time in malignant melanoma and corresponding metastases.
    Nielsen LB; Dabrosin N; Sloth K; Bønnelykke-Behrndtz ML; Steiniche T; Lade-Keller J
    Histopathology; 2018 Apr; 72(5):814-825. PubMed ID: 29119584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteomic Profiling of Archived Tissue of Primary Melanoma Identifies Proteins Associated with Metastasis.
    Shapanis A; Lai C; Sommerlad M; Parkinson E; Healy E; Skipp P
    Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33142795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction and monitoring of relapse in stage III melanoma using circulating tumor DNA.
    Tan L; Sandhu S; Lee RJ; Li J; Callahan J; Ftouni S; Dhomen N; Middlehurst P; Wallace A; Raleigh J; Hatzimihalis A; Henderson MA; Shackleton M; Haydon A; Mar V; Gyorki DE; Oudit D; Dawson MA; Hicks RJ; Lorigan P; McArthur GA; Marais R; Wong SQ; Dawson SJ
    Ann Oncol; 2019 May; 30(5):804-814. PubMed ID: 30838379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.